Medicine and Dentistry
Acute Pulmonary Embolism
77%
Afterload
21%
Anticoagulation
8%
Apoplexy
12%
Artificial Respiration
11%
Atrial Fibrillation
10%
Blood Clot Lysis
11%
Brain Ischemia
12%
Cardiac Computed Tomography
10%
Cardiac Magnetic Resonance Imaging
8%
Chronic Thromboembolic Pulmonary Hypertension
46%
Cohort Analysis
8%
Echocardiography
16%
Endarterectomy
26%
Fibrosis
12%
Heart Function
13%
Heart Output
12%
Heart Right Ventricle Failure
100%
Heart Right Ventricle Function
8%
Heart Ventricle Remodeling
8%
Hemodynamic
28%
Hypoxia
10%
Iloprost
8%
Inotropism
10%
Levosimendan
28%
Lung Artery Pressure
20%
Lung Vascular Resistance
23%
Magnetic Resonance Imaging
9%
Mechanical Thrombectomy
8%
Nitric Oxide
14%
Obstruction
8%
Out of Hospital Cardiac Arrest
11%
Patent Foramen Ovale
12%
Peripheral Vasodilating Agent
10%
Persistent Truncus Arteriosus
12%
Pulmonary Artery
11%
Pulmonary Circulation
7%
Pulmonary Embolism
84%
Pulmonary Embolism Response Team
13%
Pulmonary Hypertension
47%
Right Ventricle
34%
Right Ventricular Function
41%
Right Ventricular Hypertrophy
52%
Semaxanib
12%
Sildenafil
24%
Stroke Volume
18%
Systolic Blood Pressure
24%
Transesophageal Echocardiography
10%
Treprostinil
9%
Vasodilatation
9%
Pharmacology, Toxicology and Pharmaceutical Science
5 Hydroxydecanoic Acid
5%
Adrenergic Receptor
5%
Amine Oxidase (Flavin Containing) Isoenzyme A
5%
Antifibrotic Agent
5%
Biological Marker
15%
Bisoprolol
5%
Brain Ischemia
12%
Cerebrovascular Accident
6%
Chronic Thromboembolic Pulmonary Hypertension
49%
Cohort Study
8%
Disease Course
5%
Dopamine Beta Monooxygenase
5%
Empagliflozin
5%
Experimental Pulmonary Hypertension
5%
Fibrosis
11%
Heart Right Ventricle Failure
56%
Heart Right Ventricle Hypertrophy
21%
Heart Ventricle Remodeling
13%
Hospital Mortality
5%
Hypoxia
10%
Ischemia
5%
Levosimendan
11%
Losartan
5%
Lung Embolism
40%
Mercaptopurine
5%
Monocrotaline Pyrrole
5%
Mortality Rate
8%
Mouse
5%
Nitric Oxide
5%
Obstruction
7%
Patent Foramen Ovale
11%
Peripheral Vasodilating Agent
7%
Phosphodiesterase V
6%
Pirfenidone
5%
Porcine Model
7%
Prostacyclin
11%
Pulmonary Hypertension
45%
Reperfusion Injury
5%
Riociguat
5%
Semaxanib
12%
Survival Rate
5%
Terlipressin
5%
Transient Ischemic Attack
5%
Treprostinil
7%
Tricuspid Valve Regurgitation
5%
Venous Thromboembolism
11%
Wistar Rat
8%
Wound Healing
5%
Keyphrases
Aortic Valve-in-valve
5%
Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
5%
High-risk Pulmonary Embolism
5%
Inotropic Effect
5%
Isolated Rat Heart
5%
Monoamine Oxidase A (MAO-A)
5%
Monocrotaline Pyrrole
5%
Patent Foramen Ovale Closure
5%
Pneumonectomy
5%
Pressure Overload
5%
Prostacyclin
5%
Pulmonary Artery
5%
Pulmonary Artery Systolic Pressure
6%
Pulmonary Embolism
5%
Recurrent Ischemic Stroke
5%
Right Heart Hemodynamics
5%
Right Ventricular
6%
Right Ventricular Adaptation
5%
Right Ventricular Function
8%
Right Ventricular Hypertrophy
5%
Right Ventricular-pulmonary Arterial Coupling
5%
Supplemental Oxygen
5%
Transient Ischemic Attack
5%
Tricuspid Annular Plane Systolic Excursion (TAPSE)
5%
Valve Implantation
5%
Ventricular Pressure
5%